Streetbeat News

Regulatory

MA

V

Mastercard (NYSE:MA) and MoonPay have announced a partnership to explore how Web3 tools can enhance experiential marketing and connect with consumers. MoonPay will use Mastercard's Crypto Credential system and integrate payments technology like Mastercard Send and Click to Pay. Otherlife, MoonPay’s subsidiary, will play a key role in the partnership. Visa Inc (NYSE:V) has also been active in the Web3 space, extending its stablecoin settlement capabilities to the Solana blockchain and partnering with Bitcoin rewards app Fold.

Portfolio Pulse from Khyathi Dalal

October 25, 2023 | 10:19 pm

JUSHF

Jumal George, a New York marijuana dispensary worker, is facing a cannabis-related felony charge in Pennsylvania, where marijuana remains illegal. This situation highlights the clash between state and federal marijuana laws. Meanwhile, Pennsylvania State Senators have filed a bill proposing the legalization of marijuana for adults aged 21 and above. Jushi Holdings Inc. (OTCQX:JUSHF) has expressed support for this bill, citing potential economic and social benefits.

Portfolio Pulse from Joana Scopel

October 25, 2023 | 9:49 pm

META

Meta's CFO has announced plans to allocate more headcount towards AI, infrastructure, Reality Labs, monetization, and regulatory needs, according to Reuters.

Portfolio Pulse from Charles Gross

October 25, 2023 | 9:32 pm

BIIB

ESALY

Eisai has presented new interim study results for its investigational subcutaneous formulation LEQEMBI, which is being studied for use in early Alzheimer's disease. The formulation has shown to clear 14% more plaque than IV, with pharmacokinetics 11% higher and similar ARIA rates to IV. Additionally, 76% of patients showed no decline and 60% showed clinical improvement at 18 months in a low-Tau subpopulation in an additional analysis of Clarity AD.

Portfolio Pulse from Benzinga Newsdesk

October 25, 2023 | 9:28 pm

ALNY

Alnylam Pharmaceuticals has published the results of its APOLLO-B Phase 3 study of Patisiran in patients with Cardiomyopathy of ATTR Amyloidosis in the New England Journal of Medicine. The results of the study could have significant implications for the company's future.

Portfolio Pulse from Benzinga Newsdesk

October 25, 2023 | 9:21 pm

AAC

X-Energy Reactor Company and the U.S. Department of Energy (DOE) have signed a cooperative agreement to advance the development of a mobile microreactor design. The agreement supports X-energy's work on the preliminary design of its transportable nuclear power plant. The DOE has awarded approximately $2.5 million to X-energy for this project. The Department of Defense (DOD) has also expanded its agreement with X-energy to develop a cost-effective design for a transportable advanced nuclear microreactor prototype for use in remote military locations.

Portfolio Pulse from Benzinga Newsdesk

October 25, 2023 | 9:21 pm

OPK

OPKO Health, Inc. (NASDAQ:OPK) will present new clinical data on RAYALDEE, an extended-release calcifediol, at the American Society of Nephrology Kidney Week in November 2023. The data will demonstrate that RAYALDEE effectively raises serum levels of 25-hydroxyvitamin D and 1,25-dihydroxyvitamin D in non-dialysis patients with secondary hyperparathyroidism, making it an alternative to vitamin D hormone therapies. The data also support early initiation of treatment with RAYALDEE to delay disease progression.

Portfolio Pulse from Benzinga Newsdesk

October 25, 2023 | 9:19 pm

NLSP

NLS Pharmaceutics has received a Nasdaq minimum bid price notification, indicating that the company's stock has not met the minimum bid price requirement for continued listing on the Nasdaq Capital Market.

Portfolio Pulse from Benzinga Newsdesk

October 25, 2023 | 9:18 pm

LIAN

LianBio (NASDAQ:LIAN) has presented efficacy and safety data from a Phase 2a study of infigratinib in Chinese patients with advanced gastric cancer at the ESMO Congress 2023. The study showed a confirmed objective response rate of 23.8% and a disease control rate of 76.2%. The drug was well tolerated with no treatment-related adverse events leading to dose discontinuation, death, or drug-induced liver injury. Infigratinib has received Breakthrough Therapy Designation from the China National Medical Products Administration for the treatment of gastric cancer.

Portfolio Pulse from Benzinga Newsdesk

October 25, 2023 | 9:00 pm

RKLB

Rocket Lab USA, Inc. (NASDAQ:RKLB) has received authorization from the Federal Aviation Administration (FAA) to resume Electron launches after an in-flight anomaly on September 19th. The FAA confirmed that Rocket Lab's launch license remains active. The company is finalizing a review into the anomaly's root cause and expects to complete it in the coming weeks. Rocket Lab anticipates a return to flight later this quarter with corrective measures in place.

Portfolio Pulse from Benzinga Newsdesk

October 25, 2023 | 8:46 pm